Theradiag: Very Strong Revenue Growth at End-September 2016: +31%

  • Very high growth in LISA TRACKER® sales: x2.4
  • Revenues generated by in-house products stable at 74%

CROISSY-BEAUBOURG & MONTPELLIER, France--()--Regulatory News:

THERADIAG (Paris:ALTER) (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics and theranostics, has today reported its consolidated revenues for the 3rd quarter of 2016.

Theradiag’s sales performances over the first half of 2016 continued in the 3rd quarter, notably for Theranostics activity, which has seen revenues multiplied by 2.4. The monitoring of biotherapies, whose clinical and economic interest has been confirmed by recent publications, is becoming a must for numerous clinicians and pharmaceutical companies”, commented Professor Gérard Tobelem, Theradiag’s Chairman.

     
In thousands of euros  

September 30
2016

 

September 30
2015

  Change
Revenues   6,380   4,873   +31%
o/w Lisa Tracker® revenues   2,484   1,033   x2.4
o/w IVD revenues   3,896   3,840   +1%
 

Over the first 9 months of the year ending September 30, 2016, Theradiag recorded consolidated revenues of €6.4 million, up +31% compared with the same period of 2015. This growth was notably driven by the Theranostic Business Unit and the strong growth in Lisa Tracker® sales (x2.4 compared with end of September 2015 sales).

Revenues for the 3rd quarter of 2016 totaled €1.7 million, up 20% compared with the 3rd quarter of 2015.

The 3rd quarter of 2016 saw two major events:

  • the launch in the United States, by Janssen Biotech, of the 2Inform program to offer monitoring tests to help healthcare professionals better use Remicade® in treating patients with inflammatory bowel diseases (IBD);
  • the €2.5 million capital increase fully subscribed by HOB Biotech, which now has a 10.77% stake in the Company. This investment will help accelerate market penetration for all of the products available on the BioCLIA instrument in Europe.

Michel Finance, Theradiag’s Chief Executive Officer, added: Our confidence in Theradiag’s future is maintained based on the revenue growth at the end of September. In the short and medium term, this growth is being driven by the current or future agreements with pharmaceutical companies.

About Theradiag

Capitalizing on its expertise in the distribution, development and manufacturing of in vitro diagnostic tests, Theradiag innovates and develops theranostics tests (combining treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases, cancer and AIDS. Theradiag notably markets the Lisa Tracker® range (CE marked), which is a comprehensive multiparameter theranostic solution for patients with autoimmune diseases treated with biotherapies. With its subsidiary Prestizia, Theradiag is developing new biomarkers based on microRNAs for the diagnosis and monitoring of rectal cancer, auto-immune and inflammatory diseases and HIV/AIDS. Theradiag is thus participating in the development of customized treatment, which favors the individualization of treatments, the evaluation of their efficacy and the prevention of drug resistance. The Company is based in Marne-la-Vallée, near Paris, and in Montpellier, and has over 75 employees.

For more information about Theradiag, please visit our website: www.theradiag.com

Contacts

Theradiag
Investor Relations
Fabienne François
CFO
+33 (0)1 64 62 10 12
contact@theradiag.com
pr
NewCap
Financial Communications
& Investor Relations
Valentine Brouchot
+33 (0)1 44 71 94 94
theradiag@newcap.eu
or
Alize RP
Press Relations
Caroline Carmagnol /
Florence Portejoie
+33 (0)1 44 54 36 64
theradiag@alizerp.com

Contacts

Theradiag
Investor Relations
Fabienne François
CFO
+33 (0)1 64 62 10 12
contact@theradiag.com
pr
NewCap
Financial Communications
& Investor Relations
Valentine Brouchot
+33 (0)1 44 71 94 94
theradiag@newcap.eu
or
Alize RP
Press Relations
Caroline Carmagnol /
Florence Portejoie
+33 (0)1 44 54 36 64
theradiag@alizerp.com